

## **Press Release**

### **Eurocor announces interim results of the Freeway™ Stent Study at IROS Congress**

- **Freeway™ drug-eluting balloon for treatment of *de novo* lesions in the SFA or popliteal arteries**
- **The trend shows a low TLR rate of 2.5% for Freeway™**

**Bonn, Germany – January 18, 2013 – [Eurocor GmbH](#)**, an Opto Circuits group company, unveiled interim results of the ongoing Freeway Stent Study on January 17<sup>th</sup>, 2013 at IROS (Interventionell Radiologische Olbert Symposium), Berlin, Germany. The study was presented during the Free Paper Session 2 by Prof. Dr. Josef Tacke, Klinikum Passau, Germany. The multicenter, open, prospective randomized trial investigates the prevention of restenosis by drug-eluting balloon (DEB) dilatation (Freeway™) after stenting with a Nitinol stent versus, dilatation with standard balloon (POBA) after stenting with a Nitinol stent in the treatment of Superficial Femoral Artery (SFA) or Popliteal artery (PI-segment) lesions in the legs.

#### **Interim Results**

The trend shows a very low target lesion revascularization (TLR) rate of 2.5%, whereas the second group of 39 patients that have been treated with the Nitinol stent and POBA are showing a TLR rate of 10.2 %. Also a higher rate of primary patency for the DEB arm compared to the POBA arm (86.1% vs. 75.7%, respectively) has been found. These findings are reflected in a significant better clinical outcome regarding Rutherford classification (0.25±0.66 vs. 0.69±0.97, respectively; p=0.02).

#### **About the Trial**

The randomized, prospective clinical study is being conducted in 15 European sites to investigate the rate of clinically driven target lesion revascularization (TLR). 200 patients suffering from *de novo* lesions that need to be stented are enrolled and are randomized in a 1:1 ratio. Both groups will be treated with Nitinol stent implantation following postdilatation with a drug-eluting balloon (Freeway™ DEB) or a standard balloon



(POBA), randomized in a 1:1 ratio. The Primary Endpoint is the rate of clinically driven target lesion revascularization (TLR) at 6 months. After 6<sup>th</sup> and 12<sup>th</sup> month, the patients will undergo a duplex follow-up or an angiographic follow-up (a clinical FU at 12 month will finalize the study). The analysis is performed by an independent core lab.

Currently 111 patients have been enrolled, whereof a 6 month follow-up is now available for 79 patients. 40 of them have been treated with a Nitinol stent and a DEB.

Prof. Dr. Josef Tacke commented: “In-stent restenosis is a serious problem in the SFA and PI-segment. Drug-eluting balloons might be an option to prevent restenosis at an early stage for patients that need to be stented. The interim results are very promising and we are looking forward to the final results of the study.”

“The trend so far shows a good and safe performance of our drug-eluting balloon Freeway™. Especially the already significant outcome regarding the Rutherford Classification is good news. We trust that our DEB technology platform used in the Freeway™ Stent Study will offer treatment options and significant therapeutic advantages for the patients,” said Dr. Rembert Pogge von Strandmann, Vice President Clinical & Regulatory, Eurocor.

-End-

### Media Contact

Eurocor GmbH

Claudia Tischendorf

Phone: +49 (0) 228 201 50 26

Email: [pressoffice@eurocor.de](mailto:pressoffice@eurocor.de)

### The Company:

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Europe. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group.

For more information, please visit [eurocor.de](http://eurocor.de) and [optocircuits.com](http://optocircuits.com).

**Eurocor GmbH**  
**One heartbeat ahead®**

**Eurocor GmbH**  
In den Dauen 6a  
53117 Bonn  
Germany

T + 49 (0) 228 20 1500  
F + 49 (0) 228 20 1505  
[pressoffice@eurocor.de](mailto:pressoffice@eurocor.de)  
[eurocor.de](http://eurocor.de)

Eurocor is a wholly owned subsidiary of Opto Eurocor Healthcare and is part of the Opto Circuits Group – [optocircuits.com](http://optocircuits.com)